Every 8-K that ELITE HEALTH SYSTEMS (EHSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EHSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EHSI filings page.
Elite Health Systems Inc. entered into a financing with its CEO, Dr. Prasad Jeereddi, consisting of a $525,000 subordinated note and an accompanying warrant. The note is unsecured, bears 10% annual interest, includes a 2% prepayment penalty, and matures on July 31, 2027.
The warrant allows Dr. Jeereddi to purchase up to 110,526 shares of common stock at $0.95 per share, exercisable in whole or part through July 31, 2031, including on a cashless basis if the shares are not then registered. These warrant shares are currently unregistered and subject to transfer restrictions. The agreement permits additional investment on the same terms up to an aggregate of $1.5 million.
Elite Health Systems Inc. reports that its Board of Directors has authorized management to review, consider and pursue strategic alternatives for the company. Options under review include raising equity or debt capital, selling certain assets or operating businesses, or engaging in other strategic financings or transactions such as a merger or a disposition of all of its assets.
The company notes there is no timetable for completing any transaction and there is no assurance any strategic transaction will be completed or will increase stockholder value. The Board may terminate the review at any time. Elite Health Systems states that failure to consummate a strategic transaction, including a financing, merger, sale or disposition of all or substantially all assets, or other alternative, could have a material adverse effect on its liquidity, financial condition and ability to continue operations, while it continues to operate in the ordinary course and focus on its Medicare Advantage business.
Elite Health Systems Inc. reported the results of a Special Meeting of Stockholders held on September 26, 2025. A total of 21,939,924 common shares were eligible to vote, and 14,688,791 votes were cast, establishing a quorum.
Stockholders voted on director nominees and additional proposals. Director vote totals disclosed include: Dr. Prasad Jeereddi with 14,632,106 votes for and 56,685 against; Alan Gold with 14,633,106 for and 55,685 against; William Leimkuhler with 14,633,106 for and 55,685 against; William St. Lawrence with 14,633,106 for and 55,685 against; and Dr. Haranath Policherla with 14,688,791 for, 0 against, and 0 abstentions.
The filing also lists proposal vote counts as follows: 14,487,901 for and 200,890 against; 14,497,016 for and 191,775 against; 14,031,106 for, 157,685 against, and 500,000 abstentions; 14,688,791 for, 0 against, and 0 abstentions; and 14,622,906 for and 65,885 against.
Elite Health Systems Inc. entered into a Share Exchange Agreement to acquire 100% of Physician Support Systems, Inc. (“PSS”) from its stockholders. As consideration, Elite Health Systems will issue 3,158,000 shares of its common stock to the PSS selling stockholders.
The transaction involves related parties, as Chief Executive Officer Dr. Prasad Jeereddi owns 46% of PSS and his daughter, Dr. Praveena Jeereddi, owns 44%. The deal is not yet closed and is contingent on stockholder approval of the Exchange Agreement, an amendment to increase authorized common shares, and satisfaction of specified closing conditions and deliverables.